More news: Health / Surgery
Agency / Source: NEC Corporation

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Nagasaki University and NEC OncoImmunity Collaborate to Design Universal Vaccines Targeting Tropical Infectious Diseases - Nagasaki University and NEC OncoImmunity (NOI) have announced that they will collaborate to use NOI’s AI platform to design universal vaccines against highly pathogenic and tropical infectious diseases - Nagasaki-U.ac.jp / OncoImmunity.com / NEC.com
Nagasaki University and NEC OncoImmunity Collaborate to Design Universal Vaccines Targeting Tropical Infectious Diseases

 

PRZOOM - /newswire/ - Nagasaki, Japan, 2023/08/21 - Nagasaki University and NEC OncoImmunity (NOI) have announced that they will collaborate to use NOI’s AI platform to design universal vaccines against highly pathogenic and tropical infectious diseases - Nagasaki-U.ac.jp / OncoImmunity.com / NEC.com. NEC; TSE: 6701

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Health / Surgery Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The collaboration between NOI and Nagasaki University (nagasaki-u.ac.jp )aims to harness the power of advanced AI to optimize vaccine designs to be universally and broadly protective against certain pathogen families prevalent in tropical regions. Under the scope of the collaboration, the AI technology from NOI will be used to design both T cell and B cell vaccines. Nagasaki University will subsequently validate the designs using their extensive "wet-lab" capabilities and convalescent donor samples collected from their extensive network of tropical field stations.

This collaboration has also led to the establishment of the Department of Vaccine Informatics at the Institute of Tropical Medicine, Nagasaki University. The department, led by Dr. Trevor Clancy, Chief Scientific Officer of NOI, will employ its AI technology to support the Nagasaki University team in conducting basic research aimed at understanding the immune correlates of protection across a range of tropical diseases. Members of NEC's AI drug development team will also participate in this department.

Professor Takeshi Nagayasu, M.D., Ph.D., Trustee (Strategic Development and Research), Nagasaki University

“We are delighted to embark on this collaboration with NEC OncoImmunity in our pursuit of designing universal vaccines targeting tropical infectious diseases. By combining the expertise of Nagasaki University in tropical medicine with the advanced AI technology of NEC, we aim to make significant strides in vaccine development for the benefit of global health. And with plans to hire more up-and-coming researchers, we hope to turn our newly established Department of Vaccine Informatics into a world-class research center for AI-based infection control.”

Richard Stratford, CEO of NOI, expressed his enthusiasm about the collaboration, stating:

"NOI's core AI technology is well suited for the development of universal vaccines, and we are fully committed to delivering effective vaccine designs to Nagasaki University that target highly pathogenic and tropical infectious diseases. We are immensely proud of this collaboration with such a world-renowned tropical medicine institute, and we anticipate significant outcomes from this project."

Masamitsu Kitase, Corporate Senior VP, Head of the Healthcare and Life Science Division, NEC Corporation, commented:

"The NEC Group is very excited by this collaboration with Nagasaki University, which will demonstrate interdisciplinary research between computer technology and knowledge for Tropical Medicine, and promises to make significant contributions to vaccine development. Infectious diseases have gained even more attention following the recent pandemic, and NEC is committed to using its state-of-art AI technology to develop effective vaccines in this space."

About the Institute of Tropical Medicine, Nagasaki University
The Institute of Tropical Medicine was established in 1942 as the East Asia Research Institute of Endemics, affiliated with Nagasaki Medical College, and later became the Institute of Tropical Medicine, an independent organization separate from the Medical College, in 1967. The Institute is the only research and teaching institution in Japan devoted exclusively to studying tropical diseases. The Institute is a component of the DEJIMA Infectious Disease Research Alliance (DIDA), which was established at the University to comprehensively and strategically manage the University's infectious disease research resources. Within DIDA, the University operates a "World-Leading R&D Center for Vaccine Development Program," funded by SCARDA* for five universities in Japan. The development of vaccines using artificial intelligence (AI) is one of the main pillars of Nagasaki University's vaccine R&D program.

*SCARDA:The "Strategic Center of Biomedical Advanced Vaccine Research and Development for Preparedness and Response” set up under Japan Agency for Medical Research and Development (AMED) and serves as a command post to coordinate vaccine development in Japan.

About NEC OncoImmunity

NEC OncoImmunity AS (oncoimmunity.com) is an AI-driven biotechnology company that has developed proprietary machine learning-based software which addresses the key knowledge gaps in the prediction of bona fide immunogenic neoantigens for personalized cancer immunotherapy. The AI technology can be used to identify optimal neoantigen targets for truly personalized cancer vaccines & cell therapies in a clinically actionable timeframe, and also facilitate effective patient selection for cancer immunotherapy. The AI technology has also been repurposed to identify optimal antigens from pathogens for the purpose of designing broadly protective vaccines against highly diverse viral species and viral genera, that are effective in the global population.

About NEC Corporation

NEC Corporation (nec.com) has established itself as a leader in the integration of IT and network technologies while promoting the brand statement of "Orchestrating a brighter world." NEC enables businesses and communities to adapt to rapid changes taking place in both society and the market as it provides for the social values of safety, security, fairness and efficiency to promote a more sustainable world where everyone has the chance to reach their full potential.

NEC is a registered trademark of NEC Corporation. All Rights Reserved. Other product or service marks mentioned herein are the trademarks of their respective owners. ©2023 NEC Corporation.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Health / Surgery Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: NEC Corporation

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]  / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Health / Surgery articles,
CATCH Visitors via Your Competitors Announcements!


Nagasaki University and NEC OncoImmunity Collaborate to Design Universal Vaccines Targeting Tropical Infectious Diseases

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
NEC’s AI Drug Development | The Institute of Tropical
Contact: Press Office - NEC.com 
+81 3-3454-1111
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any NEC Corporation securities in any jurisdiction including any other companies listed or named in this release.

Health / Surgery via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Press Releases From NEC Corporation / Company Profile


Read Health / Surgery Most Recent Related Press Releases:

GenieMD Awarded Frost & Sullivan’s 2024 Company of the Year Award for Pioneering Virtual Chronic Disease Management Solutions
Health Recovery Solutions (HRS) Applauded by Frost & Sullivan for Transforming Remote Care Delivery with its Clinically Enabled, Patient-centric RPM
Greenway Health Earns Frost & Sullivan’s 2023 North American Revenue Cycle Management Customer Value Leadership Award for Consistently Delivering Prod
Verista Awarded by Frost & Sullivan for Providing Next-Generation Compliance and Quality Management Solutions in the Life Sciences Industry
TeraRecon Applauded by Frost & Sullivan for Solving Time-related Challenges in Neurological Care and its Market-leading Position
Subang Jaya Medical Centre Awarded Frost & Sullivan’s Company of the Year Award for the Third Consecutive Year
Sunway Medical Centre Velocity Awarded by Frost & Sullivan for Leading the Malaysian Hospital Industry with Holistic Medical Care
George Clinical Applauded by Frost & Sullivan for its Competitive Differentiation and Leadership in Strategy Execution in the Asia Pacific Region
AvantGuard Applauded by Frost & Sullivan for Extending the Life of Chlorine-based Disinfectants for Sustained Efficacy with its Residual Antimicrobial
Infor and HARMAN Announce Strategic Partnership on Healthcare Delivery

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
.



PREMIUM Members


Visit  BizJobs.com

Visit  JobsWare.com

Visit  Limelon Advertising, Co.







 
  ©2005-2024 PRZOOM - Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today